Apollo Therapeutics Funding Round

1/2/2024

Venture Equity

$33,500,000

Series C

The company intends to use the funds to advance pipeline programs through clinical development and further fund its drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, license or acquire additional clinical stage programs that meet strict selection criteria.

Private & Independent

Biopharmaceutical

3rd Floor 22 Station Road
Cambridge, England, CB1 2JD
UK

Undisclosed

Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo's portfolio-based model combines a centralized team of drug development 'architects' and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner -- prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease.